Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk's New Weight Loss Shot Loses To Rival Eli Lilly In Clinical Trial—Stock Plummets
Novo Nordisk's experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly's Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo announced Monday, causing its stock to collapse in pre-market trading.
Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
Novo Nordisk shares have fallen 16.4% over the past six months. However, I believe Wall Street is still underestimating the prospects of semaglutide at a dose of 25 mg. Even excluding its approval in late December last year, Wegovy generated DKK 79.1 billion in net revenues for Novo Nordisk in 2025, a 35.9% increase year-on-year.
5 Things to Know Before the Stock Market Opens
Stocks are pointing to a lower open amid tariff uncertainty after major indexes posted gains last week; President Donald Trump is imposing new tariffs to replace the ones the Supreme Court struck down on Friday, starting with a 15% global tariff; earnings from Nvidia, Home Depot, Lowe's, Salesforce and other major companies headline a busy week that will also include Trump's State of the Union address; Novo Nordisk shares are slumping after the Ozempic and Wegovy maker disappointed in its latest clinical trial for its next-generation weight-loss drug; and thousands of flights are being delayed or canceled across the East Coast this morning as a blizzard hits the region. Here's what you need to know today.
Novo Nordisk Is Under Pressure - And Trading At A Discount
Novo Nordisk is facing its toughest period in years, yet it remains a 'Strong Buy' and a compelling long-term investment. Novo Nordisk's recent results and 2026 outlook disappointed, with sales and profits under pressure from competition, copycats, and mandated price cuts. Despite near-term headwinds, Novo Nordisk's wide moat, robust pipeline, and historical double-digit growth support confidence in long-term high-single-digit to low-double-digit growth.
Novo Nordisk: The Possible Upside
Weight loss treatments provider Novo Nordisk might have experienced a sharp stock decline after disappointing 2025 results and 2026 outlook, but it has seen an impressive bounce back since. While the expected financial weakness is a real downer, there's a possibility of a sales surprise this year considering the company's recent vigorous actions as well as promising launches. NVO's forward P/E has fallen so low now that further upside looks unmistakable. This is especially true as the company is expected to return to improved financial health from 2027.
Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU
Patients on the higher dose of 7.2 milligrams for about 18 months lost 21% of their body weight on average, a study found.
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.
Novo Nordisk plans Wegovy vials amid obesity-drug competition
Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials. “We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said.
Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start
Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what's been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share in the blockbuster weight loss drug market.
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to obesity treatments, expected later this year, to open up overnight.
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?
NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.
Novo Nordisk target cut by Deutsche Bank despite long-term optimism
Deutsche Bank has cut its price target for Novo Nordisk (NYSE:NVO) by 16% to DKK400 following a turbulent week for the Danish pharmaceutical group, citing revenue headwinds, management uncertainty and clinical trial risks. Emmanuel Papadakis, equity analyst at Deutsche Bank, described the period post fourth-quarter results as “the best of times, the worst of times”, reflecting a mix of strong product potential and acute business volatility.
